Novo Nordisk has appointed Poul Weihrauch, CEO of Mars, as a board observer for its 2026/2027 term. In this role, he will leverage his commercial and supply-chain expertise from leading a top fast-moving consumer goods company to inform strategic decisions for its GLP-1 weight-loss drug portfolio, including Ozempic and Wegovy.

The company intends to nominate Weihrauch as a full board member at its 2027 AGM, typically held in March. His deep consumer-market knowledge and brand strategy experience are expected to support Novo Nordisk’s efforts to address evolving patient and market needs as demand for appetite suppressant medications grows.

With rising GLP-1 medication adoption influencing consumer behavior in food and beverage markets, Novo Nordisk aims to leverage cross-industry insights to anticipate shifts in product demand. Weihrauch’s appointment signals a strategic priority on integrating consumer goods expertise into pharmaceutical growth initiatives.